Meridian Bioscience (FRA:MR4) Change In Payables And Accrued Expense : €1.0 Mil (TTM As of Sep. 2022)

View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Change In Payables And Accrued Expense?

Meridian Bioscience's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2022 was €-1.7 Mil. It means Meridian Bioscience's Accounts Payable & Accrued Expense declined by €1.7 Mil from Jun. 2022 to Sep. 2022 .

Meridian Bioscience's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2022 was €1.6 Mil. It means Meridian Bioscience's Accounts Payable & Accrued Expense increased by €1.6 Mil from Sep. 2021 to Sep. 2022 .

Meridian Bioscience Change In Payables And Accrued Expense Historical Data

The historical data trend for Meridian Bioscience's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Change In Payables And Accrued Expense Chart

Meridian Bioscience Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.09

-0.47

7.37

5.11

1.62

Meridian Bioscience Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															9.00	1.89	5.88	-5.03	-1.70

Meridian Bioscience Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.0 Mil.

Meridian Bioscience Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Meridian Bioscience (FRA:MR4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (FRA:MR4) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

3471 River Hills Drive, Cincinnati, OH, USA, 45244

Website

https://www.meridianbioscience.com

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Meridian Bioscience (FRA:MR4) Headlines

No Headlines